As a therapeutic drug for breast cancer, Tamoxifen (TAM) has better pharmacological activity only after the formation of 4-hydroxy-N-demethylamoxifen (Endoxifen), which is a metabolite catalyzed by CYP2D6 (Kleina et al., 2013). This evidence concerns the gene CYP2D6 and breast carcinoma.